Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 1995 Jan;87(1):19–24.

Compliance with public sector HIV medical care.

P Kissinger 1, D Cohen 1, W Brandon 1, J Rice 1, A Morse 1, R Clark 1
PMCID: PMC2607741  PMID: 7869402

Abstract

Despite the availability of free or low-cost public sector human immunodeficiency virus (HIV) health-care services, important inequities in utilization exist. This study examined two measures of compliance with HIV medical care: attendance of scheduled outpatient visits and use of the emergency room. Clients of two public HIV outpatient clinics were followed from time of health-care initiation to either death or the end of the study. The association of race, sex, age, and injection drug use (IDU) with these measures were examined in multivariate logistic regression. Models were adjusted for disease staging at time of entry and for length of follow-up time in clinic. Of 1824 clients followed, 15% failed to attend scheduled visits and 18.1% had at least one emergency room visit. Clients who missed visits were more likely to be African American, to have a history of IDU, and to have a CD4 cell count < 500/mm3 or an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection at entry. They were also more likely to have > or = 12 months of follow-up time in the HIV clinic, but were less likely to have entered into health care from an early intervention clinic. Clients who had at least one emergency room visit were more likely to be African American, female, IDU, and under 22 years of age; these clients were also more likely to have entered with CD4 < 200/mm3 or with an opportunistic infection, and to have > or = 12 months of follow-up in the clinic.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
24

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aboulker J. P., Swart A. M. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. Lancet. 1993 Apr 3;341(8849):889–890. doi: 10.1016/0140-6736(93)93096-j. [DOI] [PubMed] [Google Scholar]
  2. Bloom J. N., Palestine A. G. The diagnosis of cytomegalovirus retinitis. Ann Intern Med. 1988 Dec 15;109(12):963–969. doi: 10.7326/0003-4819-109-12-963. [DOI] [PubMed] [Google Scholar]
  3. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  4. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  5. Graham N. M., Zeger S. L., Park L. P., Vermund S. H., Detels R., Rinaldo C. R., Phair J. P. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med. 1992 Apr 16;326(16):1037–1042. doi: 10.1056/NEJM199204163261601. [DOI] [PubMed] [Google Scholar]
  6. Hamilton J. D., Hartigan P. M., Simberkoff M. S., Day P. L., Diamond G. R., Dickinson G. M., Drusano G. L., Egorin M. J., George W. L., Gordin F. M. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992 Feb 13;326(7):437–443. doi: 10.1056/NEJM199202133260703. [DOI] [PubMed] [Google Scholar]
  7. Harris J. E. Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987. JAMA. 1990 Jan 19;263(3):397–401. [PubMed] [Google Scholar]
  8. Henderly D. E., Freeman W. R., Causey D. M., Rao N. A. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 1987 Apr;94(4):425–434. doi: 10.1016/s0161-6420(87)33454-2. [DOI] [PubMed] [Google Scholar]
  9. Klein R. S. Prophylaxis of opportunistic infections in individuals infected with HIV. AIDS. 1989;3 (Suppl 1):S161–S173. doi: 10.1097/00002030-198901001-00024. [DOI] [PubMed] [Google Scholar]
  10. McKinney M. M., Wieland M. K., Bowen G. S., Goosby E. P., Marconi K. M. States' responses to Title II of the Ryan White CARE Act. Public Health Rep. 1993 Jan-Feb;108(1):4–11. [PMC free article] [PubMed] [Google Scholar]
  11. McLeod G. X., Hammer S. M. Zidovudine: five years later. Ann Intern Med. 1992 Sep 15;117(6):487–501. doi: 10.7326/0003-4819-117-6-487. [DOI] [PubMed] [Google Scholar]
  12. Neighbors H. W. Seeking professional help for personal problems: black Americans' use of health and mental health services. Community Ment Health J. 1985 Fall;21(3):156–166. doi: 10.1007/BF00754731. [DOI] [PubMed] [Google Scholar]
  13. Piette J. D., Mor V., Mayer K., Zierler S., Wachtel T. The effects of immune status and race on health service use among people with HIV disease. Am J Public Health. 1993 Apr;83(4):510–514. doi: 10.2105/ajph.83.4.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rosenberg P. R., Uliss A. E., Friedland G. H., Harris C. A., Small C. B., Klein R. S. Acquired immunodeficiency syndrome. Ophthalmic manifestations in ambulatory patients. Ophthalmology. 1983 Aug;90(8):874–878. [PubMed] [Google Scholar]
  15. Russell K., Jewell N. Cultural impact of health-care access: challenges for improving the health of African Americans. J Community Health Nurs. 1992;9(3):161–169. doi: 10.1207/s15327655jchn0903_4. [DOI] [PubMed] [Google Scholar]
  16. Seage G. R., 3rd, Hertz T., Stone V. E., Epstein A. M. The effects of intravenous drug use and gender on the cost of hospitalization for patients with AIDS. J Acquir Immune Defic Syndr. 1993 Jul;6(7):831–839. [PubMed] [Google Scholar]
  17. Smith M. E., Baker C. R., Branch L. G., Walls R. C., Grimes R. M., Karklins J. M., Kashner M., Burrage R., Parks A., Rogers P. Case-mix groups for VA hospital-based home care. Med Care. 1992 Jan;30(1):1–16. doi: 10.1097/00005650-199201000-00001. [DOI] [PubMed] [Google Scholar]
  18. Solomon L., Frank R., Vlahov D., Astemborski J. Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. Am J Public Health. 1991 Oct;81(10):1285–1290. doi: 10.2105/ajph.81.10.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES